Priorities of human papillomavirus-associated oropharyngeal cancer patients at diagnosis and after treatment.
Adult
Aged
Chemoradiotherapy, Adjuvant
/ adverse effects
Counseling
Decision Making, Shared
Disease Progression
Female
Follow-Up Studies
Human papillomavirus 16
/ isolation & purification
Humans
Male
Middle Aged
Neoplasm Recurrence, Local
Oropharyngeal Neoplasms
/ mortality
Oropharynx
/ drug effects
Papillomavirus Infections
/ mortality
Patient Preference
/ statistics & numerical data
Prognosis
Prospective Studies
Surveys and Questionnaires
/ statistics & numerical data
Time Factors
Treatment Outcome
Xerostomia
/ etiology
Decision-making
HPV
Head and neck neoplasms
Oropharyngeal neoplasms
Patient preference
Journal
Oral oncology
ISSN: 1879-0593
Titre abrégé: Oral Oncol
Pays: England
ID NLM: 9709118
Informations de publication
Date de publication:
08 2019
08 2019
Historique:
received:
04
04
2019
revised:
13
05
2019
accepted:
18
05
2019
entrez:
27
7
2019
pubmed:
28
7
2019
medline:
7
7
2020
Statut:
ppublish
Résumé
Little is known regarding how human papillomavirus-positive oropharyngeal cancer (HPV-OPC) patient goals change with treatment. This study evaluates whether patient ranking of non-oncologic priorities relative to cure and survival shift after treatment as compared to priorities at diagnosis. This is a prospective study of HPV-OPC patient survey responses at diagnosis and after treatment. The relative importance of 12 treatment-related priorities was ranked on an ordinal scale (1 as highest). Median rank (MR) was compared using Wilcoxon matched-pairs signed-rank tests. Prevalence of high concern for 11 treatment-related issues was compared using paired t-test. The effect of patient characteristics on change in priority rank and concern was evaluated using linear regression. Among 37 patients, patient priorities were generally unchanged after treatment compared with at diagnosis, with cure and survival persistently ranked top priority. Having a moist mouth uniquely rose in importance after treatment. Patient characteristics largely did not affect change in priority rank. Concerns decreased after treatment, except concern regarding recurrence. Treatment-related priorities are largely similar at diagnosis and after treatment regardless of patient characteristics. The treatment experience does not result in a shift of priorities from cure and survival to non-oncologic domains over cure and survival. The rise in importance of moist mouth implies that xerostomia may have been underappreciated as a sequelae of treatment. A decrease in most treatment-related concerns is encouraging, whereas the persistence of specific areas of concern may inform patient counseling.
Identifiants
pubmed: 31345377
pii: S1368-8375(19)30163-0
doi: 10.1016/j.oraloncology.2019.05.016
pmc: PMC6662631
mid: NIHMS1531417
pii:
doi:
Types de publication
Journal Article
Research Support, N.I.H., Extramural
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
11-15Subventions
Organisme : NIDCR NIH HHS
ID : P50 DE019032
Pays : United States
Organisme : NIDCR NIH HHS
ID : R35 DE026631
Pays : United States
Informations de copyright
Copyright © 2019 Elsevier Ltd. All rights reserved.
Références
Support Care Cancer. 2017 Dec;25(12):3775-3783
pubmed: 28702685
Breast. 2016 Apr;26:31-45
pubmed: 27017240
Head Neck. 2004 Feb;26(2):163-70
pubmed: 14762885
Lancet Oncol. 2011 Feb;12(2):127-36
pubmed: 21236730
N Engl J Med. 2010 Jul 1;363(1):24-35
pubmed: 20530316
Eur J Cancer Care (Engl). 2018 Jan;27(1):
pubmed: 29024186
Crit Rev Oncol Hematol. 2016 Jun;102:47-54
pubmed: 27061883
J Clin Oncol. 2013 Dec 20;31(36):4550-9
pubmed: 24248688
Radiother Oncol. 2018 Jan;126(1):75-80
pubmed: 29229507
J Clin Oncol. 2000 Feb;18(4):877-84
pubmed: 10673531
Oral Oncol. 2018 Aug;83:147-153
pubmed: 30098771
Am J Med. 2012 Jun;125(6):545-7
pubmed: 22483059
Oral Oncol. 2018 Sep;84:88-94
pubmed: 30115482
Int J Surg. 2006;4(1):37-44
pubmed: 17462312
J Clin Oncol. 2013 Feb 10;31(5):543-50
pubmed: 23295795
Am J Surg Pathol. 2012 Dec;36(12):1874-82
pubmed: 23060353
Br J Oral Maxillofac Surg. 2018 Apr;56(3):161-167
pubmed: 29395443
Int J Radiat Oncol Biol Phys. 2019 Mar 1;103(3):646-653
pubmed: 30395903
J Affect Disord. 2012 Dec 10;141(2-3):343-51
pubmed: 22727334
Cancer. 2019 Apr 15;125(8):1281-1289
pubmed: 30645761
Eur J Oncol Nurs. 2014 Oct;18(5):512-20
pubmed: 24877858
Patient Educ Couns. 2015 Sep;98(9):1046-57
pubmed: 26138158
J Clin Oncol. 2014 Oct 20;32(30):3365-73
pubmed: 24958820
Med Decis Making. 2003 Jul-Aug;23(4):281-92
pubmed: 12926578
Br J Oral Maxillofac Surg. 2015 Oct;53(8):711-8
pubmed: 26055236
Int J Radiat Oncol Biol Phys. 2017 Aug 1;98(5):1022-1027
pubmed: 28721884
J Natl Cancer Inst. 2008 Feb 20;100(4):261-9
pubmed: 18270337
Clin Oncol (R Coll Radiol). 2011 Oct;23(8):518-24
pubmed: 21550217
Oral Oncol. 2016 Dec;63:23-29
pubmed: 27938996
J Clin Oncol. 1993 Mar;11(3):570-9
pubmed: 8445433
Cancer. 2017 Apr 1;123(7):1156-1165
pubmed: 28195638
Oral Oncol. 2016 Sep;60:90-5
pubmed: 27531878
Semin Radiat Oncol. 2018 Jan;28(1):46-52
pubmed: 29173755